Shire files Adderall patent suit against Barr, Impax Laboratories

By Jennifer Chiou

New York, Oct. 20 - Shire Pharmaceuticals Group plc said its subsidiary Shire Laboratories Inc. filed a lawsuit against Barr Laboratories, Inc. and Impax Laboratories, Inc. for infringement of Shire's U.S. Patent No. 6,913,768 in the U.S. District Court of the Southern District of New York.

The lawsuit results from abbreviated new drug applications filed by Barr and Impax seeking FDA approval to market and sell generic versions of Shire's 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg Adderall XR products.

Shire obtained the patent on July 5.

Based in Basingstoke, England, Shire is a pharmaceutical company focused on central nervous system, gastrointestinal, renal diseases and human genetic therapies. Adderall is its lead Attention Deficit Hyperactivity Disorder medication.

The current case is neither expected to affect a patent suit between Shire and Barr in the Southern District of New York, which is scheduled to go to trial in January, nor additional patent litigation between Shire and Impax slated to go to trial on Feb. 23, 2006.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.